Gresonitamab

Tax included
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma.
MedChemExpress 
HY-P99350

Data sheet

Size
Multiple sizes
Reactivity
CD3
Application
Cancer-programmed cell death
CAS
2413817-97-5